Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

Modern Pathology

Volumn 20, Issue 5, 2007, Pages 538-544

  Mehra, Rohit ^a   Tomlins, Scott A ^a   Shen, Ronglai ^a   Nadeem, Owais ^a   Wang, Lei ^a   Wei, John T ^a   Pienta, Kenneth J ^a   Ghosh, Debashis ^a   Rubin, Mark A ^b,c   Chinnaiyan, Arul M ^a   Shah, Rajal B ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Fluorescent in situ hybridization; Gene aberrations; Localized prostate cancer; TMPRSS2, ETS

Indexed keywords

GENOMIC DNA; MEMBRANE PROTEIN; SERINE PROTEINASE; TRANSCRIPTION FACTOR ELK 1;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FAMILY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK;

CHROMOSOME ABERRATIONS; DNA-BINDING PROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 34247363715     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800769     Document Type: Article

References (19)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648.
2. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-3400.
3. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341.
4. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006;8:465-469.
5. Perner S, Mosquera J, Demechelis F, et al. TMPRSSERG Fusion Prostate Cancer: an early molecular event associated with invasion. Am J Surg Pathol (in press).
6. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
7. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
8. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984.
9. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771.
10. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prosate cancer in a watchful waiting cohort. Oncogene 2007 January 22 [E-pub ahead of print].
11. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-319.
12. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
13. Manley S, Mucci NR, De Marzo AM, et al. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 2001;159:837-843.
14. Soller MJ, Isaksson M, Elfving P, et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-719.
15. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852.
16. Wang J, Cai Y, Ren CIttmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs Is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351.
17. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-1383.
18. Rubin MA, Bismar TA, Andren O, et al. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005; 14:1424-1432.
19. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002;2:19-27.